Brazil
Related tags
HER2 Proven Diagnostic Accuracy
Since 1988, laboratories around the world have relied on the diagnostic accuracy of Dako HER2 testing for breast cancer. Now new hope is given for patients with gastric cancer. A recent clinical study shows that HercepTest™ and HER2 FISH pharmDx™ Kit accurately identify patients with gastric cancer who may benefit from trastuzumab treatment.*
HER2 treatment now targets both patients with breast and gastric cancer indications.
*Lancet 2010; 376:687-07
Dako Gastric Cancer Literature
Dako provides a variety of material for HER2 testing in Gastric Cancer.
Click on this link for information on products, test algorithm and more:
HER2 Proven Diagnostic Accuracy Now available for Gastric cancer
(Literature Order No.: 29021)
Would you like further information?
Please contact your local Dako representative for additional material:
HercepTest™ material:
HercepTest™ - Interpretation Manual - Gastric Cancer
(Literature Order No.: 29018)
HER2 Proven Diagnostic Accuracy Now available for Gastric Cancer
(Literature Order No.: 29021)
HER2 FISH material:
HER2 FISH pharmDx™ Interpretation Guide - Gastric Cancer
(Literature Order No.: 29019)
HER2 Proven Diagnostic Accuracy Now available for Gastric Cancer
(Literature Order No.: 29021)
Guidelines for Scoring HercepTest™ - Gastric Cancer, Internal Tool
(Literature Order No.: 38647)